Can LLY & NVO Continue to Thrive After Earnings?

STLoke

05-04

$Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$ Both overrated. I don't expect any more up side

Spiders

05-02

I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.

orsiri

04-28

Lilly's Weighty Dilemma: Is the Stock a Golden Opportunity or a Bellyache?

Eli Lilly ($Eli Lilly(LLY)$) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&P 500, rubbing shoulders with tech giants like Nvidia ($NVIDIA Corp(NVDA)$) and Apple ($Apple(AAPL)$), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f

Lilly's Weighty Dilemma: Is the Stock a Golden Opportunity or a Bellyache?

TigerGPT

04-27

Q: What is Eli Lilly 2024/Q1 Earnings Preview?

TigerGPT Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German

Q: What is Eli Lilly 2024/Q1 Earnings Preview?

Grafa

04-25

Novo Nordisk (NYSE:NVO) slashes capital, cancels 45M shares

Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800. Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.

Novo Nordisk (NYSE:NVO) slashes capital, cancels 45M shares

NAI500

04-18

Does VKTX, SKYE & JANX have room to rally after rallying 269%?

Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri

Does VKTX, SKYE & JANX have room to rally after rallying 269%?

Ryan_Z0528

04-18

$LLY's Zepbound Tackles Sleep Apnea, New Catalyst for $LLY Stock?

1."Miracle Weight Loss Drug" Finds a New Purpose $Eli Lilly(LLY)$ ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera

$LLY's Zepbound Tackles Sleep Apnea, New Catalyst for $LLY Stock?

Long_Equity

04-13

My favourite sectors to invest in

My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are $Novo-Nordisk A/S(NVO)$ $IDEXX Laboratories(IDXX)$ $Genmab A/S(GMAB)$ and $Sartorius AG(SARTF)$ all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than

My favourite sectors to invest in

NAI500

04-10

Why is LLY dominating the weight loss drug market?

图片In the past 12 months, the stock price of $Eli Lilly(LLY)$ has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and $Novo-Nordisk A/S(NVO)$ still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven

Why is LLY dominating the weight loss drug market?

{"data":{"themeId":"d822d5c696d142e19279a3443143a214","name":"Can LLY & NVO Continue to Thrive After Earnings?","description":"LLY and NVO will release their financial reports this Tuesday and Thursday. \nBoth of these weight-loss drug companies have risen by over 20% since the beginning of the year.\n----------------------\nIs weight-loss drug, like AI, a main investment theme this year? \nWould you buy weight-loss drug companies? \nCan Eil Lilly return to $800?","image":"https://community-static.tradeup.com/news/41769bc30d50092aae45ad020b371b2e","type":0,"style":1,"follow":false,"createTime":1714375563855,"userCounts":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":d822d5c696d142e19279a3443143a214}&rnconfig={\"headerBarHidden\": true}","subscribe":false,"allowFollow":true,"hasReward":true,"rewardScore":1000,"rewardValidDate":1714893905000,"rewardEnd":true,"symbols":[],"tweetCounts":12,"categoryId":"7a15628ce2174325bddc6229505e0d70","options":[],"votedOptionId":"","totalUserCount":0,"followStatus":false,"themeName":"Can LLY & NVO Continue to Thrive After Earnings?","tweetAmount":12,"imageIsDefault":false},"tab":"all","allList":[{"id":302014081146904,"gmtCreate":1714753325447,"gmtModify":1714753329370,"author":{"id":"4088220260028080","authorId":"4088220260028080","name":"STLoke","avatar":"https://static.tigerbbs.com/69d7e7705000646320fe426fccb39c93","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$ </a>&nbsp;<a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$ </a>&nbsp; Both overrated. I don't expect any more up side","listText":"<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$ </a>&nbsp;<a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$ </a>&nbsp; Both overrated. I don't expect any more up side","text":"$Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$ Both overrated. I don't expect any more up side","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/302014081146904","isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":301502444765376,"gmtCreate":1714628500659,"gmtModify":1714628505253,"author":{"id":"4159970598736412","authorId":"4159970598736412","name":"Spiders","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.","listText":"I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.","text":"I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/301502444765376","isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":299968257593472,"gmtCreate":1714253859977,"gmtModify":1714375611127,"author":{"id":"4125570196865622","authorId":"4125570196865622","name":"orsiri","avatar":"https://community-static.tradeup.com/news/65ce9f1def4b96d1cd3e7dce4d696e8e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Lilly's Weighty Dilemma: Is the Stock a Golden Opportunity or a Bellyache?","htmlText":"Eli Lilly (<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a>) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&amp;P 500, rubbing shoulders with tech giants like Nvidia (<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>) and Apple (<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f","listText":"Eli Lilly (<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a>) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&amp;P 500, rubbing shoulders with tech giants like Nvidia (<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>) and Apple (<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f","text":"Eli Lilly ($Eli Lilly(LLY)$) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&P 500, rubbing shoulders with tech giants like Nvidia ($NVIDIA Corp(NVDA)$) and Apple ($Apple(AAPL)$), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f","images":[{"img":"https://community-static.tradeup.com/news/f576f744f8ffd98f3097d211b177bb30","width":"1200","height":"627"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":129,"commentSize":7,"repostSize":14,"link":"https://ttm.financial/post/299968257593472","isVote":1,"tweetType":1,"viewCount":787,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1},"content":"I wanna a slice of this juicy pie too without worrying about putting on weight 🍕🍕🍕🤗🤗🤗","text":"I wanna a slice of this juicy pie too without worrying about putting on weight 🍕🍕🍕🤗🤗🤗","html":"I wanna a slice of this juicy pie too without worrying about putting on weight 🍕🍕🍕🤗🤗🤗"}],"imageCount":2,"langContent":"EN","totalScore":0},{"id":299595247317072,"gmtCreate":1714149315484,"gmtModify":1714375611208,"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Q: What is Eli Lilly 2024/Q1 Earnings Preview?","htmlText":"<a href=\"https://ttm.financial/gpt\">TigerGPT</a> Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German","listText":"<a href=\"https://ttm.financial/gpt\">TigerGPT</a> Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German","text":"TigerGPT Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/299595247317072","isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":299065769480464,"gmtCreate":1714040233181,"gmtModify":1714375644310,"author":{"id":"4169784042383112","authorId":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Novo Nordisk (NYSE:NVO) slashes capital, cancels 45M shares","htmlText":"Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.&nbsp; Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.","listText":"Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.&nbsp; Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.","text":"Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800. Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.","images":[{"img":"https://community-static.tradeup.com/news/b07769154fb3e3fe449c76c1ec7381f9"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/299065769480464","isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":296626576699424,"gmtCreate":1713439204955,"gmtModify":1714375611447,"author":{"id":"4144906086863692","authorId":"4144906086863692","name":"NAI500","avatar":"https://community-static.tradeup.com/news/01a5cfb1c65c21d31f28a3934107c034","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Does VKTX, SKYE & JANX have room to rally after rallying 269%?","htmlText":"Shares of three biotech stocks, <a href=\"https://ttm.financial/S/VKTX\">$Viking Therapeutics(VKTX)$</a> <a href=\"https://ttm.financial/S/SKYE\">$Skye Bioscience Inc.(SKYE)$</a> <a href=\"https://ttm.financial/S/JANX\">$Janux Therapeutics, Inc.(JANX)$</a>, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> and <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri","listText":"Shares of three biotech stocks, <a href=\"https://ttm.financial/S/VKTX\">$Viking Therapeutics(VKTX)$</a> <a href=\"https://ttm.financial/S/SKYE\">$Skye Bioscience Inc.(SKYE)$</a> <a href=\"https://ttm.financial/S/JANX\">$Janux Therapeutics, Inc.(JANX)$</a>, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> and <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri","text":"Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri","images":[{"img":"https://community-static.tradeup.com/news/20a1e6998cbafabecab3121942fa5449","width":"1080","height":"662"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":125,"commentSize":1,"repostSize":14,"link":"https://ttm.financial/post/296626576699424","isVote":1,"tweetType":1,"viewCount":1138,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000575","authorId":"9000000000000575","name":"Gloria112","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"content":"You make some interesting points about these biotech stocks.","text":"You make some interesting points about these biotech stocks.","html":"You make some interesting points about these biotech stocks."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":296603990483008,"gmtCreate":1713433844938,"gmtModify":1714375611361,"author":{"id":"1436866998000","authorId":"1436866998000","name":"Ryan_Z0528","avatar":"https://static.tigerbbs.com/d65c4b5c01f61efa0ccc7644f4f6b9b9","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"$LLY's Zepbound Tackles Sleep Apnea, New Catalyst for $LLY Stock?","htmlText":"1.\"Miracle Weight Loss Drug\" Finds a New Purpose <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera","listText":"1.\"Miracle Weight Loss Drug\" Finds a New Purpose <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera","text":"1.\"Miracle Weight Loss Drug\" Finds a New Purpose $Eli Lilly(LLY)$ ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera","images":[{"img":"https://community-static.tradeup.com/news/3dd0e9e33b9276150a5ab1024fac4893","width":"1500","height":"1000"},{"img":"https://community-static.tradeup.com/news/5c314f3df7821e198866318be42b4f19","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/81094f80e1b2e94fe4aee1c6add2b1a6","width":"1672","height":"286"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":55,"commentSize":1,"repostSize":6,"link":"https://ttm.financial/post/296603990483008","isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":294703534620672,"gmtCreate":1712968536777,"gmtModify":1714375644392,"author":{"id":"4120987054613802","authorId":"4120987054613802","name":"Long_Equity","avatar":"https://community-static.tradeup.com/news/43412c9581fc7eef840624d0829cb637","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"My favourite sectors to invest in","htmlText":"My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> <a href=\"https://ttm.financial/S/IDXX\">$IDEXX Laboratories(IDXX)$</a> <a href=\"https://ttm.financial/S/GMAB\">$Genmab A/S(GMAB)$</a> and <a href=\"https://ttm.financial/S/SARTF\">$Sartorius AG(SARTF)$</a> all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than","listText":"My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> <a href=\"https://ttm.financial/S/IDXX\">$IDEXX Laboratories(IDXX)$</a> <a href=\"https://ttm.financial/S/GMAB\">$Genmab A/S(GMAB)$</a> and <a href=\"https://ttm.financial/S/SARTF\">$Sartorius AG(SARTF)$</a> all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than","text":"My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are $Novo-Nordisk A/S(NVO)$ $IDEXX Laboratories(IDXX)$ $Genmab A/S(GMAB)$ and $Sartorius AG(SARTF)$ all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/294703534620672","isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":293859571019776,"gmtCreate":1712749438802,"gmtModify":1714375644481,"author":{"id":"4144906086863692","authorId":"4144906086863692","name":"NAI500","avatar":"https://community-static.tradeup.com/news/01a5cfb1c65c21d31f28a3934107c034","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Why is LLY dominating the weight loss drug market?","htmlText":"图片In the past 12 months, the stock price of <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven","listText":"图片In the past 12 months, the stock price of <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven","text":"图片In the past 12 months, the stock price of $Eli Lilly(LLY)$ has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and $Novo-Nordisk A/S(NVO)$ still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven","images":[{"img":"https://community-static.tradeup.com/news/5f235c97d29a5fc4e596d91846629799","width":"1080","height":"674"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":165,"commentSize":2,"repostSize":16,"link":"https://ttm.financial/post/293859571019776","isVote":1,"tweetType":1,"viewCount":966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"essenList":[{"id":299968257593472,"gmtCreate":1714253859977,"gmtModify":1714375611127,"author":{"id":"4125570196865622","authorId":"4125570196865622","name":"orsiri","avatar":"https://community-static.tradeup.com/news/65ce9f1def4b96d1cd3e7dce4d696e8e","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Lilly's Weighty Dilemma: Is the Stock a Golden Opportunity or a Bellyache?","htmlText":"Eli Lilly (<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a>) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&amp;P 500, rubbing shoulders with tech giants like Nvidia (<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>) and Apple (<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f","listText":"Eli Lilly (<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a>) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&amp;P 500, rubbing shoulders with tech giants like Nvidia (<a href=\"https://ttm.financial/S/NVDA\">$NVIDIA Corp(NVDA)$</a>) and Apple (<a href=\"https://ttm.financial/S/AAPL\">$Apple(AAPL)$</a>), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f","text":"Eli Lilly ($Eli Lilly(LLY)$) has been the talk of the town, with its stock soaring a staggering 125% in the past year. As it joins the heavyweight ranks of the S&P 500, rubbing shoulders with tech giants like Nvidia ($NVIDIA Corp(NVDA)$) and Apple ($Apple(AAPL)$), it's clear that Lilly's growth trajectory is turning heads faster than a neck brace at a tennis match. Weighing the Pros and Cons: Financial Performance Breakdown Eli Lilly (LLY) Stock Price Performance (2023-2024) What's fuelling this meteoric rise, you ask? Well, imagine a world where shedding those pesky extra pounds is as easy as pie (but without the calories). Lilly's got a golden goose in the f","images":[{"img":"https://community-static.tradeup.com/news/f576f744f8ffd98f3097d211b177bb30","width":"1200","height":"627"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":129,"commentSize":7,"repostSize":14,"link":"https://ttm.financial/post/299968257593472","isVote":1,"tweetType":1,"viewCount":787,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3559581955535845","authorId":"3559581955535845","name":"koolgal","avatar":"https://static.tigerbbs.com/c05274d88ffc0434623e57350c52c70a","crmLevel":6,"crmLevelSwitch":1},"content":"I wanna a slice of this juicy pie too without worrying about putting on weight 🍕🍕🍕🤗🤗🤗","text":"I wanna a slice of this juicy pie too without worrying about putting on weight 🍕🍕🍕🤗🤗🤗","html":"I wanna a slice of this juicy pie too without worrying about putting on weight 🍕🍕🍕🤗🤗🤗"}],"imageCount":2,"langContent":"EN","totalScore":0},{"id":299595247317072,"gmtCreate":1714149315484,"gmtModify":1714375611208,"author":{"id":"4141429963588842","authorId":"4141429963588842","name":"TigerGPT","avatar":"https://community-static.tradeup.com/news/5b82af1deb17dfa8f94b4741b9ea2738","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Q: What is Eli Lilly 2024/Q1 Earnings Preview?","htmlText":"<a href=\"https://ttm.financial/gpt\">TigerGPT</a> Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German","listText":"<a href=\"https://ttm.financial/gpt\">TigerGPT</a> Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German","text":"TigerGPT Answer: 【Forecast Data】 Eli Lilly and Co (LLY) is forecasted to have an Earnings Per Share (EPS) of $2.46 for Q1 2024. The total revenue estimate is $8,922,458,560, and the EBIT estimate is $2,678,557,290 for the same quarter. Compared to Q1 2023, the EPS has increased by 51.85%, total revenue by 28.15%, and EBIT by 65.42%. These significant increases suggest a strong growth trajectory for the company, reflecting successful product launches, increased demand for its products, or improved operational efficiency. 【Quarterly Important News】 Key news over the past quarter includes: 1. German Chancellor Olaf Scholz's commitment to support the pharmaceutical industry, which could create a favorable environment for Eli Lilly's operations in German","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":1,"link":"https://ttm.financial/post/299595247317072","isVote":1,"tweetType":1,"viewCount":97,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":296603990483008,"gmtCreate":1713433844938,"gmtModify":1714375611361,"author":{"id":"1436866998000","authorId":"1436866998000","name":"Ryan_Z0528","avatar":"https://static.tigerbbs.com/d65c4b5c01f61efa0ccc7644f4f6b9b9","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"$LLY's Zepbound Tackles Sleep Apnea, New Catalyst for $LLY Stock?","htmlText":"1.\"Miracle Weight Loss Drug\" Finds a New Purpose <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera","listText":"1.\"Miracle Weight Loss Drug\" Finds a New Purpose <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera","text":"1.\"Miracle Weight Loss Drug\" Finds a New Purpose $Eli Lilly(LLY)$ ′s Zepbound,a weight loss drug, is emerging as a potential treatment for sleep apnea, aprevalent disorder linked to serious health risks.This development could be a game−changer,offering a much−needed solution for conditions that affect many,including some of my family.Its worth for us to keep an eye on Zepbound′s clinical progress—it could significantly impact LLY's future prospects. 📈🧪Eli Lilly's weight loss drug Zepbound found to reduce sleep apnea, company says2. If Zepbound proves effective for sleep apnea in trials, it could benefit:Sleep Apnea Patients: 😴 Great news for those seeking new treatments!Obese Patients: 🏋️‍♀️ As a weight loss drug, it might offer a two-for-one thera","images":[{"img":"https://community-static.tradeup.com/news/3dd0e9e33b9276150a5ab1024fac4893","width":"1500","height":"1000"},{"img":"https://community-static.tradeup.com/news/5c314f3df7821e198866318be42b4f19","width":"560","height":"240"},{"img":"https://community-static.tradeup.com/news/81094f80e1b2e94fe4aee1c6add2b1a6","width":"1672","height":"286"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":55,"commentSize":1,"repostSize":6,"link":"https://ttm.financial/post/296603990483008","isVote":1,"tweetType":1,"viewCount":703,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":3,"langContent":"EN","totalScore":0},{"id":302014081146904,"gmtCreate":1714753325447,"gmtModify":1714753329370,"author":{"id":"4088220260028080","authorId":"4088220260028080","name":"STLoke","avatar":"https://static.tigerbbs.com/69d7e7705000646320fe426fccb39c93","crmLevel":9,"crmLevelSwitch":1,"followedFlag":false},"themes":[],"htmlText":"<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$ </a>&nbsp;<a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$ </a>&nbsp; Both overrated. I don't expect any more up side","listText":"<a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$ </a>&nbsp;<a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$ </a>&nbsp; Both overrated. I don't expect any more up side","text":"$Eli Lilly(LLY)$ $Novo-Nordisk A/S(NVO)$ Both overrated. I don't expect any more up side","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/302014081146904","isVote":1,"tweetType":1,"viewCount":16,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":299065769480464,"gmtCreate":1714040233181,"gmtModify":1714375644310,"author":{"id":"4169784042383112","authorId":"4169784042383112","name":"Grafa","avatar":"https://community-static.tradeup.com/news/ec1614006170d0aa3182195a94e8944d","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Novo Nordisk (NYSE:NVO) slashes capital, cancels 45M shares","htmlText":"Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.&nbsp; Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.","listText":"Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800.&nbsp; Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.","text":"Novo Nordisk (NYSE:NVO) has successfully implemented a reduction in its share capital following shareholder approval at its Annual General Meeting on March 21, 2024. The pharmaceutical giant has reduced its B share capital from DKK 343,512,800 to DKK 339,012,800, achieved through the cancellation of 45 million B shares, each with a nominal value of DKK 0.10. This action has decreased the company’s total share capital to DKK 446,500,000, which is now divided into A shares totaling DKK 107,487,200 and B shares at DKK 339,012,800. Despite the reduction, Novo Nordisk assured stakeholders that the move will not impact its ongoing share repurchase program, which will continue as planned.","images":[{"img":"https://community-static.tradeup.com/news/b07769154fb3e3fe449c76c1ec7381f9"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/299065769480464","isVote":1,"tweetType":1,"viewCount":76,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":2,"langContent":"EN","totalScore":0},{"id":301502444765376,"gmtCreate":1714628500659,"gmtModify":1714628505253,"author":{"id":"4159970598736412","authorId":"4159970598736412","name":"Spiders","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":4,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"htmlText":"I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.","listText":"I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.","text":"I'm hesitant to invest in LLY and NVO stocks because I'm not yet familiar with these companies.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/301502444765376","isVote":1,"tweetType":1,"viewCount":33,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":296626576699424,"gmtCreate":1713439204955,"gmtModify":1714375611447,"author":{"id":"4144906086863692","authorId":"4144906086863692","name":"NAI500","avatar":"https://community-static.tradeup.com/news/01a5cfb1c65c21d31f28a3934107c034","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Does VKTX, SKYE & JANX have room to rally after rallying 269%?","htmlText":"Shares of three biotech stocks, <a href=\"https://ttm.financial/S/VKTX\">$Viking Therapeutics(VKTX)$</a> <a href=\"https://ttm.financial/S/SKYE\">$Skye Bioscience Inc.(SKYE)$</a> <a href=\"https://ttm.financial/S/JANX\">$Janux Therapeutics, Inc.(JANX)$</a>, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> and <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri","listText":"Shares of three biotech stocks, <a href=\"https://ttm.financial/S/VKTX\">$Viking Therapeutics(VKTX)$</a> <a href=\"https://ttm.financial/S/SKYE\">$Skye Bioscience Inc.(SKYE)$</a> <a href=\"https://ttm.financial/S/JANX\">$Janux Therapeutics, Inc.(JANX)$</a>, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> and <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri","text":"Shares of three biotech stocks, $Viking Therapeutics(VKTX)$ $Skye Bioscience Inc.(SKYE)$ $Janux Therapeutics, Inc.(JANX)$, have surged at least 269% so far this year. Do they have room to rise?1.Viking Therapeutics Since $Novo-Nordisk A/S(NVO)$ and $Eli Lilly(LLY)$ launched their own weight-loss treatments, both stocks have surged. VKTX is working on a GLP-1 therapeutic oral solution called VK2735. In Phase II trials, VK2735 performed even better than NVO's Wegovy or LLY's Zepbound.VKTX shares are up 269% year-to-date and could rise even higher as VK2735 advances in late-stage tri","images":[{"img":"https://community-static.tradeup.com/news/20a1e6998cbafabecab3121942fa5449","width":"1080","height":"662"}],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":125,"commentSize":1,"repostSize":14,"link":"https://ttm.financial/post/296626576699424","isVote":1,"tweetType":1,"viewCount":1138,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"9000000000000575","authorId":"9000000000000575","name":"Gloria112","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0},"content":"You make some interesting points about these biotech stocks.","text":"You make some interesting points about these biotech stocks.","html":"You make some interesting points about these biotech stocks."}],"imageCount":1,"langContent":"EN","totalScore":0},{"id":293859571019776,"gmtCreate":1712749438802,"gmtModify":1714375644481,"author":{"id":"4144906086863692","authorId":"4144906086863692","name":"NAI500","avatar":"https://community-static.tradeup.com/news/01a5cfb1c65c21d31f28a3934107c034","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"Why is LLY dominating the weight loss drug market?","htmlText":"图片In the past 12 months, the stock price of <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven","listText":"图片In the past 12 months, the stock price of <a href=\"https://ttm.financial/S/LLY\">$Eli Lilly(LLY)$</a> has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven","text":"图片In the past 12 months, the stock price of $Eli Lilly(LLY)$ has skyrocketed to triple digits, and the most significant driving force behind this surge is weight loss drugs. The weight loss drug market is poised to become a colossal $100 billion industry, and Eli Lilly's two weight loss drugs, Mounjaro and Zepbound, are both expected to become long-term blockbusters.In the weight loss drug market, Eli Lilly and $Novo-Nordisk A/S(NVO)$ still hold the lion's share. But here's the kicker: Eli Lilly is poised to continue dominating this market in the future.First, Mounjaro was approved to treat type 2 diabetes, but doctors often prescribe it as a weight loss drug, and it brought in more than $5 billion in reven","images":[{"img":"https://community-static.tradeup.com/news/5f235c97d29a5fc4e596d91846629799","width":"1080","height":"674"}],"top":1,"highlighted":1,"essential":2,"paper":2,"likeSize":165,"commentSize":2,"repostSize":16,"link":"https://ttm.financial/post/293859571019776","isVote":1,"tweetType":1,"viewCount":966,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":294703534620672,"gmtCreate":1712968536777,"gmtModify":1714375644392,"author":{"id":"4120987054613802","authorId":"4120987054613802","name":"Long_Equity","avatar":"https://community-static.tradeup.com/news/43412c9581fc7eef840624d0829cb637","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false},"themes":[],"title":"My favourite sectors to invest in","htmlText":"My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> <a href=\"https://ttm.financial/S/IDXX\">$IDEXX Laboratories(IDXX)$</a> <a href=\"https://ttm.financial/S/GMAB\">$Genmab A/S(GMAB)$</a> and <a href=\"https://ttm.financial/S/SARTF\">$Sartorius AG(SARTF)$</a> all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than","listText":"My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are <a href=\"https://ttm.financial/S/NVO\">$Novo-Nordisk A/S(NVO)$</a> <a href=\"https://ttm.financial/S/IDXX\">$IDEXX Laboratories(IDXX)$</a> <a href=\"https://ttm.financial/S/GMAB\">$Genmab A/S(GMAB)$</a> and <a href=\"https://ttm.financial/S/SARTF\">$Sartorius AG(SARTF)$</a> all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than","text":"My favourite sectors to invest in:• semiconductors• software as a service • payments• credit rating / scores• financial data• healthcareI prefer business facing services, rather than consumer facing products. Revenues are more resilient and predictable. Although I accept Hermes is something special.In healthcare, my favorites are $Novo-Nordisk A/S(NVO)$ $IDEXX Laboratories(IDXX)$ $Genmab A/S(GMAB)$ and $Sartorius AG(SARTF)$ all immediately come to mind.I’m sure AI will cause a lot of disruption. But there are plenty of reasons to invest in semis - AI is just one of them.Any Payments stocks other than","images":[],"top":1,"highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/294703534620672","isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}]}